A presentation at the NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care argues for the creation of evidence-based guidelines and national standards for cancer survivorship care, an area of the cancer spectrum that does not get the attention many feel that it deserves.
The presentation was made by Crystal S. Denlinger, M.D., a medical oncologist at Fox Chase Cancer Center and a leading advocate in the push to establish standards at Fox Chase.
Said Denlinger, "Some people are considered cured after treatment and others will continue to live with their cancer. Just because you're living with cancer doesn't mean you're not a survivor. We need to address the unique needs of both populations."
The goal of such guidelines would be to guide cancer survivors and their doctors through what are referred to as the four seasons of survival:
- Acute survivorship
- Transitional survivorship
- Extended survivorship
- Permanent survivorship
She added that guidelines should also include delineating a path from diagnosis to remission and beyond.
Source: NCCN
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...